Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SCYX 
Scynexis Inc (SCYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SCYX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.67
1 Year Target Price $4.67
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.4% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.97M USD | Price to earnings Ratio - | 1Y Target Price 4.67 |
Price to earnings Ratio - | 1Y Target Price 4.67 | ||
Volume (30-day avg) 3 | Beta 1.65 | 52 Weeks Range 0.66 - 2.29 | Updated Date 06/30/2025 |
52 Weeks Range 0.66 - 2.29 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3350.2% |
Management Effectiveness
Return on Assets (TTM) -24.32% | Return on Equity (TTM) -43.47% |
Valuation
Trailing PE - | Forward PE 2.09 | Enterprise Value -10805809 | Price to Sales(TTM) 10.26 |
Enterprise Value -10805809 | Price to Sales(TTM) 10.26 | ||
Enterprise Value to Revenue 0.44 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 39020300 | Shares Floating 34802573 |
Shares Outstanding 39020300 | Shares Floating 34802573 | ||
Percent Insiders 1.89 | Percent Institutions 29.96 |
Analyst Ratings
Rating 2 | Target Price 4.67 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Scynexis Inc
Company Overview
History and Background
Scynexis, Inc. is a biotechnology company focused on developing and commercializing novel anti-infectives to address significant unmet needs in the treatment of severe and life-threatening fungal infections. Founded in 1999, it has evolved from a research-focused company to one with a commercialized product.
Core Business Areas
- Anti-infective Development and Commercialization: Focuses on developing and commercializing novel antifungal agents to treat life-threatening infections. Primary product is Brexafemme (ibrexafungerp).
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and biotechnology industries. The organizational structure includes departments for research and development, commercialization, medical affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- Brexafemme (ibrexafungerp): Brexafemme is an oral antifungal indicated for vulvovaginal candidiasis (VVC). The product holds a modest market share within the VVC treatment market. Competitors include azole antifungals like fluconazole (Pfizer) and over-the-counter treatments.
Market Dynamics
Industry Overview
The anti-infectives market is driven by increasing rates of fungal infections, the rise of drug-resistant strains, and the need for novel therapies. Growth is fueled by an aging population and increased use of immunosuppressive therapies. The market faces challenges related to regulatory hurdles and reimbursement pressures.
Positioning
Scynexis is positioned as an innovator in the antifungal space with its novel glucan synthase inhibitor. Their competitive advantage lies in their unique mechanism of action.
Total Addressable Market (TAM)
The global antifungal market is estimated to be in the billions of dollars. Brexafemme aims to capture a portion of the VVC treatment market, which accounts for approximately 10% of the total antifungal market. Scynexis is positioned to grow within this TAM by capturing a share of existing antifungal treatments.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action (glucan synthase inhibitor)
- Oral formulation
- Commercialized product (Brexafemme)
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on single product (Brexafemme)
- Modest market share
- Dependence on third parties for manufacturing
Opportunities
- Expansion of Brexafemme indications
- Partnerships with larger pharmaceutical companies
- Development of new anti-infective agents
- Global expansion
Threats
- Competition from established antifungal agents
- Regulatory hurdles
- Reimbursement pressures
- Generic erosion
Competitors and Market Share
Key Competitors
- PFE
- MYL
Competitive Landscape
Scynexis faces intense competition from established pharmaceutical companies. Its novel mechanism of action is a key advantage, but it needs to effectively compete on price and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to the development and commercialization of Brexafemme. Revenue growth is contingent on market penetration.
Future Projections: Future growth projections rely on analyst estimates for Brexafemme sales and potential expansion of indications.
Recent Initiatives: Recent strategic initiatives may include partnerships, clinical trials, and marketing campaigns.
Summary
Scynexis is a biopharmaceutical company with a novel antifungal product in a competitive market. The company's innovative approach is a key strength, but they face challenges related to competition, commercialization, and limited resources. Future success depends on effective market penetration and potential expansion of indications for Brexafemme and the successful of the SCYX pipeline. They also depend on raising new funds. These factors can affect the companies performance in the near future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Scynexis Inc. SEC Filings
- Financial News Outlets
- Market Research Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scynexis Inc
Exchange NASDAQ | Headquaters Jersey City, NJ, United States | ||
IPO Launch date 2014-05-02 | CEO, President & Director Dr. David Gonzalez Angulo M.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 28 | Website https://www.scynexis.com |
Full time employees 28 | Website https://www.scynexis.com | ||
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.